Dublin, Aug. 15, 2014 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/qs..._lysosomal ) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.
The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular transport between lysosome and other cellular compartments.
These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate stored, cell types affected by this storage, and resulting organ involvement. Due to the high variability of these components, the clinical manifestations of even a single disease vary from person to person.
These symptoms also vary between members of the same family with identical mutations. The age of onset also varies for lysosomal storage diseases depending on the rate of substrate accumulation. Lysosomal storage diseases are classified on the basis of the substrate being accumulated or on the type of molecular defect associated with the disease. Neuronal ceroid-lipofuscinoses vary from classical lysosomal storage diseases where the component that gets accumulated is mitochondrial ATP synthase subunit C or sphingolipid activator proteins A and D.
The analysts forecast the Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Lysosomal Storage Diseases market for the period 2014-2018. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases, which include:
- Gaucher disease
- Fabry disease
- Mucopolysaccharidosis
- Pompe disease
- Cystinosis
- NPC
The report, the Global Lysosomal Storage Diseases Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Lysosomal Storage Diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Disease Overview
07. Market Landscape
08. Market Segmentation by Drug Class
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Others
19. Key Vendor Analysis
20. Other Reports in this Series
Companies Mentioned:
- Actelion Pharmaceuticals Ltd.
- BioMarin Pharmaceutical Inc.
- Genzyme Corp.
- Shire plc
- Mylan
- Pfizer
- Protalix
- Raptor
- Recordati
- Sigma-Ta
For more information visit http://www.researchandmarkets.com/research/qs..._lysosomal
Research and Markets Laura Wood, Senior Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices
